Cost-Effectiveness of Nivolumab (NIVO) Combined with Ipilimumab (IPI) Compared with Nivo and Ipi Monotherapies in The First-Line Treatment of Advanced Melanoma in The United States- Analysis Using 28-Month Overall Survival (OS) Data from Ch ...
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.218
https://www.valueinhealthjournal.com/article/S1098-3015(17)30552-1/fulltext
Title :
Cost-Effectiveness of Nivolumab (NIVO) Combined with Ipilimumab (IPI) Compared with Nivo and Ipi Monotherapies in The First-Line Treatment of Advanced Melanoma in The United States- Analysis Using 28-Month Overall Survival (OS) Data from Ch ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30552-1&doi=10.1016/j.jval.2017.08.218
First page :
A436
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
199